Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Contineum Therapeutics, Inc. Class A Common Stock

CTNM

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Last trade $9.57
Day change -$0.10 (-1.03%)
Day range $9.31 – $9.67
Volume 150,299
Market cap $380M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$379.7M
Price / earnings
—
Price / book
1.55×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.23×

Profitability

Earnings per share
-$1.62
Return on assets
-24.69%
Return on equity
-25.86%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
31.11×
Quick ratio
31.11×
Cash ratio
9.37×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$52.23M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CTNM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.98M$4.73M$5.26M$4.36M$3.94M$3.84M$4.4M$4.03M
Research and development$15.99M$12.7M$11.65M$12.76M$10.99M$14.06M$13.71M$13.02M
Total operating expenses$20.97M$17.43M$16.9M$17.12M$14.93M$17.9M$18.11M$17.05M
Operating income-$20.97M-$17.43M-$16.9M-$17.12M-$14.93M-$17.9M-$18.11M-$17.05M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$18.7M-$15.15M-$14.46M-$15.16M-$12.79M-$16.04M-$15.99M-$14.57M
Income taxes$0$0$0$0$0$0$0$0
Net income-$18.7M-$15.15M-$14.46M-$15.16M-$12.79M-$16.04M-$15.99M-$14.57M
Net income attributable to common shareholders-$18.7M-$15.15M-$14.46M-$15.16M-$12.79M-$16.04M-$15.99M-$14.57M
EBITDA-$20.89M-$17.29M-$16.82M-$17.03M-$14.85M-$17.82M-$18.03M-$16.97M
Basic earnings per share-$0.49-$0.40-$0.39-$0.49-$0.45-$0.62-$0.62-$0.56
Diluted earnings per share-$0.49-$0.40-$0.39-$0.49-$0.45-$0.62-$0.62-$0.56

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

BMY Reports Mixed Phase III Trial Results, Stock Down

Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles.

Zacks Investment Research

All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy

Contineum Therapeutics, Inc. (CTNM) has been upgraded to a Zacks Rank #2 (Buy) rating based on upward trends in earnings estimates. The upgrade reflects positivity about the company's earnings outlook and positions it in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation.

The Motley Fool

Contineum (CTNM) Q2 R&D Jumps 78%

Contineum Therapeutics reported a wider Q2 2025 net loss of $0.62 per share, driven by increased R&D expenses. The company continues developing treatments for pulmonary fibrosis, multiple sclerosis, and depression, with ongoing clinical trials for PIPE-791 and PIPE-307.

GlobeNewswire Inc.

Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.